Rexulti (brexpiprazole)
Major Depressive Disorder, Schizophrenia
Key Facts
About Otsuka Holdings
Otsuka Holdings Co., Ltd. is a multinational pharmaceutical and healthcare company founded in 1964, headquartered in Tokyo, Japan. The company has built a strong reputation in central nervous system disorders, with major commercial successes including the antipsychotic Abilify and depression treatment Rexulti. Otsuka operates globally with a focus on innovation in psychiatry, neurology, oncology, and nephrology, maintaining a robust pipeline of novel therapeutics and a commitment to addressing unmet medical needs.
View full company profileAbout Lundbeck
Lundbeck is a specialized biopharmaceutical company dedicated entirely to brain diseases, distinguishing itself as one of the few companies worldwide with this exclusive focus. The company leverages over seven decades of neuroscience expertise to develop and commercialize therapies for psychiatric and neurological disorders, including depression, schizophrenia, Alzheimer's disease, and migraine. As a 'Focused Innovator,' Lundbeck is building on its legacy to serve neuro-rare communities through bold science and deep patient commitment. The company operates globally, with approximately 1,000+ colleagues in the U.S. alone, working to deliver innovative treatments and support patient communities.
View full company profileAbout Sumitomo Pharma
Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.
View full company profileAbout Sumitomo Pharma
Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.
View full company profile